Skip to content

Diagnostic Accuracy of Endocytoscopy for Superficial Esophageal Neoplasia

Diagnostic Accuracy of Deep Learning-Assisted Multimodal Endocytoscopy for Superficial Esophageal Neoplasia and Precancerous Lesions: A Multicenter ,Prospective Study

Status
Enrolling by invitation
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06984055
Enrollment
600
Registered
2025-05-22
Start date
2025-03-11
Completion date
2026-12-01
Last updated
2025-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal Cancer, Squamous Cell

Keywords

Endocytoscopy, Esophageal Neoplasia, Precancerous Lesions, Deep Learning

Brief summary

In recent years, endocytoscopy (EC) has undergone rapid development as an advanced endoscopic technique. Characterized by real-time histological imaging and detection capabilities, EC enables visualization of living cells in the digestive mucosal layer through methylene blue staining via the endoscopic instrument channel. This technology provides ultra-magnified endocytoscopic images, allowing for identification of key cellular features including epithelial cell morphology and the shape of methylene blue-stained epithelial nuclei, thereby facilitating clear in vivo observation of microstructural characteristics in mucosal tissues - a technique commonly referred to as optical biopsy. However, current clinical application of EC in China remains limited due to insufficient practical experience and the absence of standardized diagnostic criteria for image interpretation. This study aims to comprehensively evaluate the diagnostic accuracy of domestically developed high-magnification electronic upper gastrointestinal endoscopy for esophageal carcinoma and precancerous lesions, using histopathology as the gold standard. The research objectives include establishing standardized diagnostic evaluation protocols and clarifying the clinical value of this technology through systematic validation.

Interventions

None listed

Sponsors

Ruijin Hospital
CollaboratorOTHER
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
CollaboratorOTHER
the Tenth People's Hospital affiliated to Tongji University
CollaboratorUNKNOWN
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
CollaboratorOTHER
First Affiliated Hospital of Zhejiang University
CollaboratorOTHER
Sir Run Run Shaw Hospital
CollaboratorOTHER
The Second Hospital of Nanjing Medical University
CollaboratorOTHER
Jiangsu Province Hospital of Traditional Chinese Medicine
CollaboratorOTHER
The Affiliated Hospital of Xuzhou Medical University
CollaboratorOTHER
Changhai Hospital
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

1.Patients diagnosed with superficial esophageal squamous cell carcinoma or high-grade intraepithelial neoplasia (HGIN) through endoscopic and pathological biopsy examinations, scheduled for endoscopic submucosal dissection (ESD); 2.Patients with esophageal squamous low-grade intraepithelial neoplasia (LGIN) confirmed by endoscopic and biopsy histopathological examinations within the preceding six months; 3. Patients exhibiting esophageal focal lesions detected during painless upper gastrointestinal endoscopy requiring pathological biopsy.

Exclusion criteria

1. Patients aged \<18 years or \>80 years; 2. Lesions located at the gastroesophageal junction with clinical suspicion of adenocarcinoma or precancerous lesions; 3. Patients with contraindications to sedated/anesthetized upper gastrointestinal endoscopy; 4. Patients with coagulation disorders; 5. Patients with a history of hypersensitivity to relevant medications (including anesthetics or methylene blue); 6. Patients presenting dysphagia or gastrointestinal obstructive symptoms, or those with suspected/confirmed digestive tract obstruction, stenosis, or fistulae; 7. Patients declining to provide informed consent for study participation, or any other circumstances deemed by investigators to preclude eligibility.

Design outcomes

Primary

MeasureTime frameDescription
Diagnostic accuracy10 minutessensitivity and specificity

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026